Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 23.23M | 29.05M | 124.80M | 61.28M | 55.29M | 23.80M |
Gross Profit | 21.00M | 28.14M | 96.83M | 48.15M | 46.32M | 21.74M |
EBITDA | -981.34M | -674.26M | 4.31B | -1.18B | -916.71M | -895.74M |
Net Income | -490.63M | -171.98M | 4.35B | -1.01B | -845.26M | -809.23M |
Balance Sheet | ||||||
Total Assets | 5.03B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B |
Cash, Cash Equivalents and Short-Term Investments | 4.50B | 4.89B | 6.54B | 1.68B | 2.06B | 2.13B |
Total Debt | 99.69M | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M |
Total Liabilities | 216.70M | 249.74M | 773.95M | 782.02M | 523.70M | 527.69M |
Stockholders Equity | 4.35B | 4.69B | 5.97B | 1.16B | 1.66B | 1.80B |
Cash Flow | ||||||
Free Cash Flow | -858.67M | -844.05M | -766.65M | -856.08M | -695.16M | -557.94M |
Operating Cash Flow | -851.00M | -839.45M | -765.27M | -843.39M | -677.73M | -552.14M |
Investing Cash Flow | -2.85B | -1.77B | 5.20B | -44.27M | 303.30M | -31.70M |
Financing Cash Flow | -746.95M | -1.22B | 419.36M | 499.46M | 306.79M | 456.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $8.40B | 16.41 | 179.14% | ― | 34.97% | 71.10% | |
64 Neutral | $7.47B | 15.58 | -10.84% | ― | 4.52% | -205.13% | |
58 Neutral | $9.04B | ― | 35.68% | ― | 7.62% | -55.29% | |
56 Neutral | $9.19B | ― | -36.30% | ― | 3421.98% | 49.62% | |
51 Neutral | $7.78B | -0.06 | -40.08% | 2.29% | 21.32% | -1.82% | |
51 Neutral | $6.39B | ― | -29.70% | ― | 75.01% | -13.20% | |
48 Neutral | $8.14B | 1.93 | -15.84% | ― | -85.32% | -111.82% |
Roivant Sciences Ltd. has announced a new common share repurchase program on June 24, 2025, allowing for the repurchase of up to $500 million of its common shares. This initiative follows a previous $1.5 billion repurchase program from April 2024, which has been fully utilized. The repurchase will be funded with available cash, with no set expiration date, and will depend on market conditions and other factors.